Panitumumab dye to help find lung cancer during surgery
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a special dye drug (panitumumab-IRDye800) that may help surgeons better see lung cancer areas while operating. If it works, it could improve how well cancer tissue is found and removed during planned lung surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a lung nodule or lung mass that could be cancer (primary lung cancer or spread from elsewhere)
- You are scheduled for planned lung surgery to remove the nodule/mass for diagnosis and/or cure
- You are well enough to participate (Karnofsky 70%+ or ECOG/Zubrod 0–2)
- Your blood counts and kidney function are in acceptable ranges (hemoglobin, white blood cells, platelets, creatinine)
- You have not taken another study drug in the last 30 days
- You cannot be pregnant or breastfeeding, and you must be able to consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a targeted antibody with a fluorescent dye can help surgeons see and remove pancreatic cancer during planned surgery. It’s an early-phase study, so the main goal is to see if the approach is safe and useful around the time of the operation.
This early-stage trial tests whether an injected medicine with a glowing dye (panitumumab-IRDye800) can help doctors better see pediatric brain tumors during planned surgery. If it works, it may help surgeons remove more tumor tissue safely.
This trial tests whether a medicine with a fluorescent dye (panitumumab-IRDye800) helps doctors better see certain tumors during surgery. It may help safer, more complete tumor removal for people with glioblastoma or vestibular schwannoma.
This trial tests a special imaging drug (IRDye800CW-nimotuzumab) that may help surgeons better see lung cancer tissue during planned lung surgery. Phase 1/2 looks mainly at safety and how well the imaging works to guide the operation.
This Phase 2 study tests a targeted medicine (panitumumab-IRDye800) given around the time of surgery for head and neck squamous cell cancer. It aims to improve doctors’ ability to find and remove cancer tissue during planned surgery.
This trial tests a special fluorescent dye attached to panitumumab, a cancer-targeting antibody, to help surgeons see tumor tissue more clearly during head and neck cancer surgery. The goal is to improve removal of all cancer cells while sparing healthy tissue.
Hear when a new Metastatic Malignant Neoplasm in the Lung trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.